Edition:
India

Bausch Health Companies Inc (BHC.TO)

BHC.TO on Toronto Stock Exchange

28.29CAD
11:07pm IST
Change (% chg)

$1.04 (+3.82%)
Prev Close
$27.25
Open
$27.56
Day's High
$29.11
Day's Low
$27.53
Volume
686,123
Avg. Vol
694,849
52-wk High
$36.32
52-wk Low
$23.60

Latest Key Developments (Source: Significant Developments)

Bausch Health Cos Says Court Upholds Validity And Determined Actavis' Infringement Of Patent Protecting Relistor Tablets
Thursday, 18 Jul 2019 

July 17 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH COMPANIES - COURT UPHOLDS VALIDITY AND DETERMINED ACTAVIS' INFRINGEMENT OF PATENT PROTECTING RELISTOR TABLETS.BAUSCH HEALTH COMPANIES INC- BAUSCH HEALTH IS NOT AWARE OF ANY OTHER ANDAS FILED WITH FDA SEEKING APPROVAL OF A GENERIC VERSION OF RELISTOR TABLETS.  Full Article

Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma
Thursday, 25 Apr 2019 

April 25 (Reuters) - Bausch Health Companies Inc ::SALIX ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH MITSUBISHI TANABE PHARMA TO DEVELOP AND COMMERCIALIZE LATE STAGE INVESTIGATIONAL S1P MODULATOR FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE.SALIX PHARMACEUTICALS - AFFILIATE HAS ENTERED INTO AN EXCLUSIVE LICENSING AGREEMENT WITH MITSUBISHI TANABE PHARMA TO DEVELOP AND COMMERCIALIZE MT-1303.  Full Article

Bausch Health And Johnson & Johnson Reach Deal Regarding Scope Of Indemnification Relating To Shower To Shower Covered Matters
Tuesday, 23 Apr 2019 

April 23 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH - CO AND JOHNSON & JOHNSON REACHED DEAL ON APRIL 17, REGARDING SCOPE OF INDEMNIFICATION RELATING TO SHOWER TO SHOWER COVERED MATTERS.BAUSCH HEALTH COMPANIES - AGREED TO DISMISS DEMAND FOR ARBITRATION THAT CO FILED AGAINST JOHNSON & JOHNSON TO ASSERT ITS RIGHTS TO INDEMNIFICATION.BAUSCH HEALTH COMPANIES INC - JOHNSON & JOHNSON WILL FULLY INDEMNIFY COMPANY IN COVERED MATTERS.BAUSCH HEALTH COMPANIES - DON'T BELIEVE THAT COVERED MATTERS WILL HAVE A MATERIAL IMPACT ON COMPANY'S FINANCIAL RESULTS GOING FORWARD.BAUSCH HEALTH COMPANIES - COVERED MATTERS INCLUDE PERSONAL INJURY & PRODUCTS LIABILITY ACTIONS ARISING FROM ALLEGED EXPOSURE TO SHOWER TO SHOWER BEFORE MARCH 2020.BAUSCH HEALTH - COVERED MATTERS INCLUDE CONSUMER FRAUD, CONSUMER PROTECTION, FALSE ADVERTISING, REGULATORY ACTIONS DUE TO MANUFACTURE, USE/SALE OF SHOWER TO SHOWER UP TO SEPT. 9, 2012.  Full Article

Synergy Pharmaceuticals Receives Court Approval For The Sale Of Its Assets To Bausch Health
Saturday, 2 Mar 2019 

March 1 (Reuters) - Bausch Health Companies Inc ::SYNERGY PHARMACEUTICALS RECEIVES COURT APPROVAL FOR THE SALE OF ITS ASSETS TO BAUSCH HEALTH.SYNERGY PHARMACEUTICALS INC - SALE OF CO'S ASSETS IS NOW EXPECTED TO CLOSE ON OR ABOUT MARCH 5, 2019.  Full Article

Bausch Health To Acquire Certain Assets Of Synergy Pharmaceuticals Inc.
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH TO ACQUIRE CERTAIN ASSETS OF SYNERGY PHARMACEUTICALS INC..BAUSCH HEALTH COMPANIES INC - DEAL FOR FOR A CASH PURCHASE PRICE OF APPROXIMATELY $195 MILLION AND ASSUMPTION OF CERTAIN ASSUMED LIABILITIES.BAUSCH HEALTH COMPANIES INC - BAUSCH HEALTH SERVED AS STALKING HORSE BIDDER IN A SALE PROCESS, WHICH SYNERGY CONDUCTED.  Full Article

Bausch Health to Launch Private Offering Of Senior Secured Notes And Add-On Unsecured Notes
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR SECURED NOTES AND ADD-ON UNSECURED NOTES.LAUNCHED AN OFFERING OF $500 MILLION AGGREGATE PRINCIPAL AMOUNT OF SENIOR SECURED NOTES DUE 2027.UNIT HAS LAUNCHED AN OFFERING OF $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF 8.500% SENIOR UNSECURED NOTES DUE 2027.UNSECURED NOTES WILL BE ADDITIONAL NOTES AND FORM PART OF SAME SERIES AS BHA'S EXISTING 8.500 PCT SENIOR NOTES DUE 2027.TO USE NET PROCEEDS FROM OFFERING, ALONG WITH CASH ON HAND, TO REPURCHASE $1.25 BILLION AGGREGATE PURCHASE PRICE OF OUTSTANDING NOTES.  Full Article

Bausch Health Commences Cash Tender Offers And Consent Solicitation For Up To $1.25 Bln Aggregate Purchase Price
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH COMMENCES CASH TENDER OFFERS AND CONSENT SOLICITATION FOR UP TO $1,250,000,000 AGGREGATE PURCHASE PRICE.ALSO SOLICITING CONSENTS TO CERTAIN PROPOSED AMENDMENTS TO INDENTURE GOVERNING ITS 5.625 PCT SENIOR NOTES DUE 2021.TENDER OffERS AND SOLICITATION WILL EXPIRE AT 11:59 P.M., NEW YORK CITY TIME, ON MARCH 21, 2019.NO AMENDMENTS TO INDENTURE GOVERNING 2023 NOTES ARE BEING SOUGHT.  Full Article

Bausch Health Companies Inc - Fourth Quarter GAAP Loss Per Share $0.98
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Bausch Health Companies Inc ::ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS AND PROVIDES 2019 GUIDANCE.QTRLY REVENUES OF $2.121 BILLION.QTRLY GAAP LOSS PER SHARE $0.98.SEES FULL-YEAR REVENUES IN RANGE OF $8.30 BILLION - $8.50 BILLION.SEES FULL-YEAR ADJUSTED EBITDA (NON-GAAP) IN RANGE OF $3.35 BILLION - $3.50 BILLION.Q4 EARNINGS PER SHARE VIEW $0.85, REVENUE VIEW $2.06 BILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $8.43 BILLION -- REFINITIV IBES DATA.  Full Article

Bausch Health Says FDA Is Close To Finalizing Its Review Of Duobrii; Expects Decision Shortly
Saturday, 16 Feb 2019 

Feb 15 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH PROVIDES UPDATE FOR DUOBRII FILING.BAUSCH HEALTH COMPANIES INC - FDA IS CLOSE TO FINALIZING ITS REVIEW, AND WE EXPECT A DECISION FROM FDA SHORTLY..BAUSCH HEALTH - FDA WILL BE UNABLE TO MEET 15 FEB PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR NEW DRUG APPLICATION FOR DUOBRII.  Full Article

Bausch Health Companies To Reduce Debt By Additional $76 Million
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH TO REDUCE DEBT BY ADDITIONAL $76 MILLION, BRINGING TOTAL DEBT REPAYMENT IN QUARTER TO APPROXIMATELY $400 MILLION.BAUSCH HEALTH COMPANIES INC - AFTER $76 MILLION PAYMENT, COMPANY WILL HAVE ELIMINATED ALL MANDATORY AMORTIZATION FOR Q1 OF 2019.  Full Article

Amag's female libido injectable therapy to sell at $899

Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder (HSDD).